Because AOD9604 does not stimulate IGF-1 production and lacks strong GH receptor agonism, it may present a safer alternative for long-term OA treatment [1]
As of 2026, neither compound has FDA approval, limiting prescribing to research contexts or off-label use by physicians specializing in obesity medicine or endocrinology
Its mechanism activates bodily processes that replace damaged cells with new ones, facilitating recovery from injuries and surgeries more effectively
Research and safety notice: This article is limited to chemical identity, NNMT biology, analytical research, cell experiments, animal studies, evidence limitations and UK regulation
Most patients complete 3 cycles before assessing full results, though skin improvements often become noticeable within the first cycle
Thank you x Jun 16, 2026 Ugly Bettys Beauty Boutique 75 Hyde Park Road, Peverell, Plymouth, PL3 4JN, England 5.0 2,654 reviews See all services Tracey R